Author: Christopher Walsh
Publisher: Amer Society for Microbiology
Release Date: 2003-02
As antibiotics become deactivated through resistance and emerging bacterial diseases Christopher Walsh offers new insights into antibiotic modification and design. He shows how antibiotics work on targets and reviews recent strategies for finding innovative antibiotics to replace the last generation.
Author: Santiago Ewig
Release Date: 2015-12-18
Dieses Buch bietet differenzierte Diagnostik und Therapie – was, wann, warum - zur sofortigen sicheren Anwendung. Entsprechend der neuesten Studien und Leitlinien aller wichtigen deutschen, europäischen und amerikanischen Fachgesellschaften. Es geht um eine der häufigsten akuten Erkrankungen in der Inneren Medizin in Deutschland mit erheblicher Hospital-Letalität von 4–10 % (höher als beim Myokardinfarkt). Oft wird die prognostische Bandbreite unterschätzt - auch Komplikationen und schwere Verläufe mit Multiorganversagen sind möglich. Grundlagen · Epidemiologie · Mikrobiologie und Immunologie (Differential-)Diagnostik, Prognose · Klinische Symptomatik und Untersuchungsbefunde · Radiologische Bildgebung · Labordiagnostik · Differentialdiagnostische Abgrenzung von Infektionen der unteren Atemwege (akute Bronchitis, akute Exazerbation der COPD) · Risikobeurteilung im Rahmen der Erstuntersuchung (Differential-)Therapie entsprechend Schweregrad Prävention, Nachsorge · Antimikrobiell · Adjunktiv · Bei Therapieversagen · Bei rezidivierender Pneumonie · Bei Aspirationspneumonie · In der Schwangerschaft · Als terminale Komplikation am Lebensende Strategie · Qualitätskontrolle der Behandlung · Arztbrief · Leitlinien Herausgeber Professor Dr. med. Santiago Ewig Chefarzt Thoraxzentrum Ruhrgebiet, Kliniken für Pneumologie und Infektiologie, EVK Herne und Augusta-Kranken-Anstalt Bochum.
Author: Institute of Medicine
Publisher: National Academies Press
Release Date: 2011-01-10
Years of using, misusing, and overusing antibiotics and other antimicrobial drugs has led to the emergence of multidrug-resistant 'superbugs.' The IOM's Forum on Microbial Threats held a public workshop April 6-7 to discuss the nature and sources of drug-resistant pathogens, the implications for global health, and the strategies to lessen the current and future impact of these superbugs.
Author: Richard B. Silverman
Publisher: Academic Press
Release Date: 2014-03-29
The Organic Chemistry of Drug Design and Drug Action, Third Edition, represents a unique approach to medicinal chemistry based on physical organic chemical principles and reaction mechanisms that rationalize drug action, which allows reader to extrapolate those core principles and mechanisms to many related classes of drug molecules. This new edition includes updates to all chapters, including new examples and references. It reflects significant changes in the process of drug design over the last decade and preserves the successful approach of the previous editions while including significant changes in format and coverage. This text is designed for undergraduate and graduate students in chemistry studying medicinal chemistry or pharmaceutical chemistry; research chemists and biochemists working in pharmaceutical and biotechnology industries. Updates to all chapters, including new examples and references Chapter 1 (Introduction): Completely rewritten and expanded as an overview of topics discussed in detail throughout the book Chapter 2 (Lead Discovery and Lead Modification): Sections on sources of compounds for screening including library collections, virtual screening, and computational methods, as well as hit-to-lead and scaffold hopping; expanded sections on sources of lead compounds, fragment-based lead discovery, and molecular graphics; and deemphasized solid-phase synthesis and combinatorial chemistry Chapter 3 (Receptors): Drug-receptor interactions, cation-π and halogen bonding; atropisomers; case history of the insomnia drug suvorexant Chapter 4 (Enzymes): Expanded sections on enzyme catalysis in drug discovery and enzyme synthesis Chapter 5 (Enzyme Inhibition and Inactivation): New case histories: for competitive inhibition, the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib and Abelson kinase inhibitor, imatinib for transition state analogue inhibition, the purine nucleoside phosphorylase inhibitors, forodesine and DADMe-ImmH, as well as the mechanism of the multisubstrate analog inhibitor isoniazid for slow, tight-binding inhibition, the dipeptidyl peptidase-4 inhibitor, saxagliptin Chapter 7 (Drug Resistance and Drug Synergism): This new chapter includes topics taken from two chapters in the previous edition, with many new examples Chapter 8 (Drug Metabolism): Discussions of toxicophores and reactive metabolites Chapter 9 (Prodrugs and Drug Delivery Systems): Discussion of antibody–drug conjugates
Author: Douglas Mayers
Publisher: Springer Science & Business Media
Release Date: 2009-07-06
This ? rst edition of Antimicrobial Drug Resistance grew out of a desire by the editors and authors to have a comprehensive resource of information on antimicrobial drug resistance that encompassed the current information available for bacteria, fungi, protozoa and viruses. We believe that this information will be of value to clinicians, epidemiologists, microbiologists, virologists, parasitologists, public health authorities, medical students and fellows in training. We have endeavored to provide this information in a style which would be accessible to the broad community of persons who are concerned with the impact of drug resistance in our cl- ics and across the broader global communities. Antimicrobial Drug Resistance is divided into Volume 1 which has sections covering a general overview of drug resistance and mechanisms of drug resistance ? rst for classes of drugs and then by individual microbial agents including bacteria, fungi, protozoa and viruses. Volume 2 addresses clinical, epidemiologic and public health aspects of drug resistance along with an overview of the conduct and interpretation of speci? c drug resistance assays. Together, these two volumes offer a comprehensive source of information on drug resistance issues by the experts in each topic.
Author: Steven L. Foley
Publisher: John Wiley & Sons
Release Date: 2011-08-04
Providing a broad overview of the microbial pathogens associated with hospital-acquired human illness, Techniques for the Study of Hospital Acquired Infection examines the cost-effective use of laboratory techniques in nosocomial infectious disease epidemiology and control. This concise guide addresses the cost benefits of combining modern molecular techniques with the traditional activities of infection control departments. The book is useful as a guide to hospital infection control programs as well as a text for medical practitioners, grad/medical students, researcher scientists, population biologists, molecular biologists, and microbiologists.
Author: Roger G. Finch
Publisher: Elsevier Health Sciences
Release Date: 2010-11-30
Well-respected and widely regarded as the most comprehensive text in the field, Antibiotic and Chemotherapy, 9th Edition by Drs. Finch, Greenwood, Whitley, and Norrby, provides globally relevant coverage of all types of antimicrobial agents used in human medicine, including all antiviral, antiprotozoan and anthelminthic agents. Comprehensively updated to include new FDA and EMEA regulations, this edition keeps you current with brand-new information about antiretroviral agents and HIV, superficial and mucocutaneous myscoses and systemic infections, management of the immunocompromised patient, treatment of antimicrobial resistance, plus coverage of new anti-sepsis agents and host/microbe modulators. Reference is easy thanks to a unique 3-part structure covering general aspects of treatment; reviews of every agent; and details of treatments of particular infections. Offer the best possible care and information to your patients about the increasing problem of multi-drug resistance and the wide range of new antiviral therapies now available for the treatment of HIV and other viral infections. Stay current with 21 new chapters including the latest information on superficial and mucocutaneous mycoses, systemic infections, anti-retroviral agents, and HIV. Get fresh perspectives and insights thanks to 21 newly-authored and extensively re-written chapters. Easily access information thanks to a unique 3-part structure covering general aspects of treatment; reviews of every agent; and details of treatments of particular infections. Apply the latest treatments for anti-microbial organisms such as MRSA, and multi-drug resistant forms of TB, malaria and gonorrhea. Keep up on the latest FDA and EMEA regulations.
Author: Christopher Walsh
Release Date: 2016-02-05
Antibiotics: Challenges, Mechanisms, Opportunitiesdetails the contemporary challenges for discovery, optimization, and advancement of new antibiotics. It focuses on discovery not preclinical or clinical development. Given that the few classes of clinically significant antibiotics are all small molecules, this book focuses on the molecular structures and characteristics of both natural and synthetic antibacterial agents. Antibioticsis a valuable reference for microbiologists, bacterial physiologists, geneticists, pharmacologists, and drug developers.
Author: Anne Ed Chang
Publisher: Salem Pr Inc
Release Date: 2005-01
Magill's Medical Guide provides readers with the most authoritative yet accessible reference source in its field. The Guide bridges the gap between professional medical encyclopedias and dictionaries and popular self-help guides.
Author: Ola Sköld
Publisher: John Wiley & Sons
Release Date: 2011-10-07
This book, which is the translated version of a Swedish book, combines a general introduction of a variety of antibiotics with a more in-depth discussion of resistance. The focus on resistance in learning about antibiotics will help future scientists recognize the problem antibiotics resistance poses for medicinal and drug-related fields, and perhaps trigger more research and discoveries to fight antibiotic resistant strains. Current overviews of the topic are included, along with specific discussions on the individual mechanisms (betalactams, glycopeptides, aminoglycosides, etc) used in various antibacterial agents and explanations of how resistances to those develop. Methods for counteracting resistance development in bacteria are discussed as well.
Author: Anne Chang
Publisher: Salem PressInc
Release Date: 2008
Covers diseases, disorders, treatments, procedures, specialties, anatomy, biology, and issues in an A-Z format, with sidebars addressing recent developments in medicine and concise information boxes for all diseases and disorders.